[Cefaclor in dermatological therapy (author's transl)].
Thirty patients suffering from bacteriogenic skin diseases were given cefaclor, in most cases simultaneously with classical external dermatological therapy. The results of therapy were satisfactory in 29 of the 30 patients. Only in one relatively severe case of erysipelas did the disease continue to spread despite the daily doses of 3 x 500 mg of oral cefaclor prescribed by the dosage regimen. Side-effects observed consisted of diarrhoea in one patient, and a transient slight increase of SGOT or alkaline phosphatase in another six patients.
D000469:Alkaline Phosphatase; D001219:Aspartate Aminotransferases; D002433:Cefaclor / Q000009:adverse effects / Q000627:therapeutic use*; D002506:Cephalexin / Q000031:analogs & derivatives*; D003967:Diarrhea / Q000209:etiology; D004886:Erysipelas / Q000188:drug therapy; D006801:Humans; D011512:Proteus Infections / Q000188:drug therapy; D012874:Skin Diseases, Infectious / Q000188:drug therapy*; D013203:Staphylococcal Infections / Q000188:drug therapy; D013290:Streptococcal Infections / Q000188:drug therapy
D002433:Cefaclor; D001219:Aspartate Aminotransferases; D000469:Alkaline Phosphatase; D002506:Cephalexin
Cefaclor in der Dermatologie.